At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach​

  • Driven by science, our mission is to revolutionize the immunotherapy treatment landscape, focusing on the development of novel, adaptable, and accessible CD8+ T cell-based technologies.​
  • Our transformative platform is first in its class, offering a unique methodology that combines innovative and established approaches to elicit a superior CD8+ T cell response. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+ T cell responses.
  • With potential applications across a range of cancers and chronic infectious diseases, our proprietary technology provides us with a robust pipeline. Our lead product, VRON-0200, is under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV) – a first-in-human clinical study is planned to initiate in late 2022.
  • Founded in 2018 to advance technology licensed from The Wistar Institute, we have assembled a world-class management team and an industry-leading global Board of Directors, with proven experience in the biotechnology sector, as well as extensive preclinical and clinical expertise in antiviral, vaccine, oncology, and immuno-oncology.​

First-In-Class Technology

  • Integrated T cell Immunotherapies
    • Superior CD8+ T cell responses: Simplicity, potency, & durability​
  • Novel checkpoint modifiers​
    • Lead programs include a locally acting B- and T-lymphocyte attenuator (BTLA) checkpoint modifier​
    • Others in development​
  • Preclinical data validate and inform our clinical development across diverse therapeutic indications​

Our Pipeline

  • VRON-0200: Establish as the CD8+ T cell immuno-modulator for HBV functional cure​
    • In clinic within a year​
  • VRON-0100: In development for HPV-induced cancers and pre-cancerous lesions ​
  • VRON-0300 and Discovery Programs: Additional oncology indication and continued development of new technologies and assets​

World-class Leadership​

  • World-class scientific founder, advisors, and board members​
  • Highly experienced team with extensive and diverse expertise and networks to successfully advance programs and achieve corporate goals​

Expert Leadership Built on Collaboration